Bio Rad Laboratories Stock Cash And Equivalents
| BIO Stock | USD 332.91 7.33 2.25% |
Bio Rad Laboratories fundamentals help investors to digest information that contributes to Bio Rad's financial success or failures. It also enables traders to predict the movement of Bio Stock. The fundamental analysis module provides a way to measure Bio Rad's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bio Rad stock.
| Last Reported | Projected for Next Year | ||
| Cash And Equivalents | 499.3 M | 549.9 M |
Bio | Cash And Equivalents |
Bio Rad Laboratories Company Cash And Equivalents Analysis
Bio Rad's Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current Bio Rad Cash And Equivalents | 434.21 M |
Most of Bio Rad's fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bio Rad Laboratories is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Bio Cash And Equivalents Driver Correlations
Understanding the fundamental principles of building solid financial models for Bio Rad is extremely important. It helps to project a fair market value of Bio Stock properly, considering its historical fundamentals such as Cash And Equivalents. Since Bio Rad's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Bio Rad's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Bio Rad's interrelated accounts and indicators.
Click cells to compare fundamentals
Bio Cash And Equivalents Historical Pattern
Today, most investors in Bio Rad Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Bio Rad's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's cash and equivalents growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Bio Rad cash and equivalents as a starting point in their analysis.
Bio Rad Cash And Equivalents |
| Timeline |
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
| Competition |
In accordance with the recently published financial statements, Bio Rad Laboratories has 434.21 M in Cash And Equivalents. This is 47.1% lower than that of the Life Sciences Tools & Services sector and 22.18% lower than that of the Health Care industry. The cash and equivalents for all United States stocks is 83.93% higher than that of the company.
Bio Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bio Rad's direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Bio Rad could also be used in its relative valuation, which is a method of valuing Bio Rad by comparing valuation metrics of similar companies.Bio Rad is currently under evaluation in cash and equivalents category among its peers.
Bio Rad ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Bio Rad's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Bio Rad's managers, analysts, and investors.Environmental | Governance | Social |
Bio Fundamentals
| Return On Equity | -0.0979 | ||||
| Return On Asset | 0.0186 | ||||
| Profit Margin | (0.30) % | ||||
| Operating Margin | 0.1 % | ||||
| Current Valuation | 9.1 B | ||||
| Shares Outstanding | 22.92 M | ||||
| Shares Owned By Insiders | 15.57 % | ||||
| Shares Owned By Institutions | 79.96 % | ||||
| Number Of Shares Shorted | 651.7 K | ||||
| Price To Earning | 2.90 X | ||||
| Price To Book | 1.24 X | ||||
| Price To Sales | 3.62 X | ||||
| Revenue | 2.67 B | ||||
| Gross Profit | 1.57 B | ||||
| EBITDA | (608.26 M) | ||||
| Net Income | (637.32 M) | ||||
| Cash And Equivalents | 434.21 M | ||||
| Cash Per Share | 62.03 X | ||||
| Total Debt | 1.41 B | ||||
| Debt To Equity | 0.16 % | ||||
| Current Ratio | 5.50 X | ||||
| Book Value Per Share | 267.46 X | ||||
| Cash Flow From Operations | 374.94 M | ||||
| Short Ratio | 3.36 X | ||||
| Earnings Per Share | (28.06) X | ||||
| Price To Earnings To Growth | 1.19 X | ||||
| Target Price | 402.33 | ||||
| Number Of Employees | 7.7 K | ||||
| Beta | 0.94 | ||||
| Market Capitalization | 9.33 B | ||||
| Total Asset | 12.3 B | ||||
| Retained Earnings | 9.26 B | ||||
| Working Capital | 2.53 B | ||||
| Current Asset | 466.61 M | ||||
| Current Liabilities | 208.93 M | ||||
| Net Asset | 12.3 B |
About Bio Rad Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bio Rad Laboratories's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bio Rad using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bio Rad Laboratories based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Bio Rad
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bio Rad position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bio Rad will appreciate offsetting losses from the drop in the long position's value.Moving against Bio Stock
| 0.4 | VCNX | Vaccinex | PairCorr |
| 0.4 | FBRX | Forte Biosciences Trending | PairCorr |
| 0.38 | VALN | Valneva SE ADR | PairCorr |
| 0.35 | HLN | Haleon plc | PairCorr |
The ability to find closely correlated positions to Bio Rad could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bio Rad when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bio Rad - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bio Rad Laboratories to buy it.
The correlation of Bio Rad is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bio Rad moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bio Rad Laboratories moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bio Rad can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Bio Rad Piotroski F Score and Bio Rad Altman Z Score analysis. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio Rad. If investors know Bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio Rad listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 5.412 | Earnings Share (28.06) | Revenue Per Share 90.815 | Quarterly Revenue Growth 0.028 | Return On Assets 0.0186 |
The market value of Bio Rad Laboratories is measured differently than its book value, which is the value of Bio that is recorded on the company's balance sheet. Investors also form their own opinion of Bio Rad's value that differs from its market value or its book value, called intrinsic value, which is Bio Rad's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio Rad's market value can be influenced by many factors that don't directly affect Bio Rad's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bio Rad's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Rad is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Rad's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.